Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 6

See more details

Referenced in 4 patents
26 readers on Mendeley
  • Article usage
  • Citations to this article (32)

Advertisement

Research Article Free access | 10.1172/JCI113821

Protease inhibitors suppress the in vitro and in vivo replication of rotavirus.

S L Vonderfecht, R L Miskuff, S B Wee, S Sato, R R Tidwell, J D Geratz, and R H Yolken

Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Find articles by Vonderfecht, S. in: JCI | PubMed | Google Scholar

Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Find articles by Miskuff, R. in: JCI | PubMed | Google Scholar

Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Find articles by Wee, S. in: JCI | PubMed | Google Scholar

Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Find articles by Sato, S. in: JCI | PubMed | Google Scholar

Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Find articles by Tidwell, R. in: JCI | PubMed | Google Scholar

Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Find articles by Geratz, J. in: JCI | PubMed | Google Scholar

Division of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

Find articles by Yolken, R. in: JCI | PubMed | Google Scholar

Published December 1, 1988 - More info

Published in Volume 82, Issue 6 on December 1, 1988
J Clin Invest. 1988;82(6):2011–2016. https://doi.org/10.1172/JCI113821.
© 1988 The American Society for Clinical Investigation
Published December 1, 1988 - Version history
View PDF
Abstract

Rotaviruses are major causes of infectious gastroenteritis in humans and other animals. We found that a variety of protease inhibitors suppressed the replication of the SA-11 strain of rotavirus in MA-104 cell cultures. Three of these compounds, leupeptin, pentamidine, and bis (5-amidino-2-benzimidazolyl) methane (BABIM) also restricted the intestinal replication of the murine strain of rotavirus when protease inhibitor and virus were administered simultaneously to suckling mice. Repeated administration of BABIM resulted in significantly reduced levels of intestinal rotaviral antigen even if administration of the compound was begun as late as 48 h after viral inoculation. Additionally, BABIM-treated animals had significantly less intestinal replication of rotavirus than did placebo-treated controls when placed in a heavily rotavirus-contaminated environment. The use of protease inhibitors represents a novel approach to the control of this important gastrointestinal pathogen and is a potential modality for the prevention and treatment of diseases caused by other enteric viruses, for which proteolytic cleavage is necessary for efficient replication.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2011
page 2011
icon of scanned page 2012
page 2012
icon of scanned page 2013
page 2013
icon of scanned page 2014
page 2014
icon of scanned page 2015
page 2015
icon of scanned page 2016
page 2016
Version history
  • Version 1 (December 1, 1988): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 6
  • Article usage
  • Citations to this article (32)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 4 patents
26 readers on Mendeley
See more details